Solventum Corp. Net Assets
Solventum Corp. net assets. Based on the latest financial reports, Solventum Corp. (SOLV) has net assets worth $4.80 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.24 Billion) and total liabilities ($9.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Solventum Corp. growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.80 Billion |
| % of Total Assets | 33.7% |
| Annual Growth Rate | -19.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 51.36 |
Net Assets of Solventum Corp. (2021–2025)
Net assets of Solventum Corp. from 2021 to 2025. This chart illustrates how Solventum Corp.'s net assets have evolved over time, based on quarterly financial data. See how leveraged is Solventum Corp.'s balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Solventum Corp. (2021–2025)
The table below shows the annual net assets of Solventum Corp. from 2021 to 2025. For live market cap and overall valuation, see SOLV stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.05 Billion | +70.63% |
| 2024-12-31 | $2.96 Billion | -74.64% |
| 2023-12-31 | $11.67 Billion | -0.65% |
| 2022-12-31 | $11.74 Billion | -2.63% |
| 2021-12-31 | $12.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solventum Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 179700000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Solventum Corp. Net Assets Breakdown (December 2025)
Solventum Corp. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.80 Billion | 35.59% |
| Common Stock | $2.00 Million | 0.04% |
| Other Comprehensive Income | $-625.00 Million | -12.38% |
| Other Components | $3.88 Billion | 76.75% |
| Total Equity | $5.05 Billion | 100.00% |
Solventum Corp. Competitors by Market Cap
The table below lists competitors of Solventum Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenwan Hongyuan Group Co Ltd
SHE:000166
|
$13.85 Billion |
|
Evolution Gaming Group AB (publ)
F:E3G
|
$13.86 Billion |
|
METSO OUTOTEC UNS.ADR 1/2
F:M6QB
|
$13.91 Billion |
|
Assurant, Inc.
NYSE:AIZ
|
$13.93 Billion |
|
Pershing Square Inc.
NYSE:PS
|
$13.84 Billion |
|
Euronext N.V.
PA:ENX
|
$13.83 Billion |
|
VERBUND AG
VI:VER
|
$13.83 Billion |
|
KT&G Corp
KO:033780
|
$13.80 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solventum Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,959,000,000 to 5,049,000,000, a change of 2,090,000,000 (70.6%).
- Net income of 1,556,000,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 431,000,000.
- Other factors increased equity by 103,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.56 Billion | +30.82% |
| Other Comprehensive Income | $431.00 Million | +8.54% |
| Other Changes | $103.00 Million | +2.04% |
| Total Change | $- | 70.63% |
Book Value vs Market Value Analysis
This analysis compares Solventum Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.16x to 2.82x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $69.92 | $81.33 | x |
| 2022-12-31 | $68.08 | $81.33 | x |
| 2023-12-31 | $67.55 | $81.33 | x |
| 2024-12-31 | $17.04 | $81.33 | x |
| 2025-12-31 | $28.80 | $81.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solventum Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 30.82%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.69%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 2.83x
- Recent ROE (30.82%) is above the historical average (16.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 12.11% | 17.87% | 0.58x | 1.17x | $254.10 Million |
| 2022 | 11.44% | 16.52% | 0.60x | 1.16x | $168.80 Million |
| 2023 | 11.54% | 16.42% | 0.59x | 1.20x | $179.40 Million |
| 2024 | 16.19% | 5.80% | 0.57x | 4.89x | $183.10 Million |
| 2025 | 30.82% | 18.69% | 0.58x | 2.83x | $1.05 Billion |
Industry Comparison
This section compares Solventum Corp.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,520,089,226
- Average return on equity (ROE) among peers: -106.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solventum Corp. (SOLV) | $4.80 Billion | 12.11% | 1.97x | $13.84 Billion |
| Akoya Biosciences Inc (AKYA) | $7.59 Million | -728.97% | 15.46x | $64.44 Million |
| Align Technology Inc (ALGN) | $83.56 Million | -41.84% | 0.81x | $10.73 Billion |
| AngioDynamics Inc (ANGO) | $37.23 Million | 8.44% | 0.34x | $495.58 Million |
| AptarGroup Inc (ATR) | $1.17 Billion | 17.51% | 1.22x | $7.66 Billion |
| AtriCure Inc (ATRC) | $30.69 Million | -44.69% | 0.27x | $2.21 Billion |
| Avinger Inc (AVGR) | $6.89 Million | -286.47% | 2.46x | $1.52 Million |
| Avantor Inc (AVTR) | $2.67 Billion | 4.36% | 2.70x | $9.19 Billion |
| Azenta Inc (AZTA) | $542.40 Million | -43.63% | 0.22x | $1.35 Billion |
| Baxter International Inc (BAX) | $8.16 Billion | 30.62% | 2.20x | $11.89 Billion |
| Becton Dickinson and Company (BDX) | $2.49 Billion | 19.29% | 1.03x | $48.93 Billion |
About Solventum Corp.
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressing… Read more